GlassScriptPhysician profile
Grant J Rasmussen
NPI 1275563751
$1,894.00
in general payments reported to CMS, 2019-2025
24 companies · $63.77 in 2025
The $63.77 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $184 · 2021: $444 · 2022: $356 · 2023: $319 · 2024: $325 · 2025: $63.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $757.38 | 2021-2025 | |
| Mylan Specialty L.P. | $304.10 | 2019-2024 | Yupelri, Yupelri |
| Glaxosmithkline, LLC. | $91.99 | 2019-2021 | |
| Pfizer INC. | $80.50 | 2019-2021 | |
| Allergan, INC. | $74.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $74.34 | 2020-2022 | |
| Novo Nordisk INC | $70.24 | 2020-2023 | Rybelsus |
| Merck Sharp & Dohme LLC | $62.32 | 2019-2021 | |
| Boston Scientific Corporation | $54.46 | 2024 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $49.70 | 2020-2021 | |
| Lilly USA, LLC | $43.68 | 2019-2024 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $27.47 | 2022 | |
| Amgen INC. | $27.41 | 2022 | |
| Sunovion Pharmaceuticals INC. | $24.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.65 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $18.62 | 2024 | Keveyis |
| Ultragenyx Pharmaceutical INC. | $16.88 | 2021 | |
| Innovation Technologies INC | $15.56 | 2024 | Irrisept |
| Sanofi Pasteur INC. | $15.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.16 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.71 | 2024 | Voquezna |
| Lucid Diagnostics INC. | $13.24 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.12 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Rasmussen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.